

-17-

What is claimed is:

1. A method of increasing the immunogenicity of a carbohydrate antigen, comprising  
conjugating the antigen to tetanus toxin Fragment C to yield a conjugated vaccine, wherein upon administration of the conjugated vaccine to a patient the Fragment C increases the potency of the antigen.
2. The method according to claim 1, wherein the antigen is a capsular polysaccharide from a bacterium.
3. The method according to claim 2, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X; Streptococcus group A, B, and C; Pneumococcus types 1,2, 3,4, 6A, 6B, 9, 14, 18F, 19F and 23; Staphylococcus aureus types 5 and 8 and Haemophilus influenzae type b.
4. The method according to claim 1, wherein the antigen is a capsular polysaccharide from a fungus.
5. The method according to claim 4, wherein the fungus is selected from the group consisting Candida albicans and Cryptococcus neoformans.
6. A method of immunizing a patient against an infection, comprising administering to the patient an effective dose of a vaccine comprising an antigen that has been conjugated to Fragment C.
7. The method according to claim 6, wherein the antigen is a capsular polysaccharide from a bacterium.

-18-

8. The method according to claim 7, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X; Streptococcus group A, B, and C; Pneumococcus types 1,2, 3, 4, 6A, 6B, 9, 14, 18F, 19F and 23; Staphylococcus aureus types 5 and 8 and Haemophilus influenzae type b.

9. The method according to claim 6, wherein the antigen is a capsular polysaccharide from a fungus.

10. The method according to claim 9, wherein the fungus is selected from the group consisting Candida albicans and Cryptococcus neoformans.

11. A conjugated vaccine comprising an antigen that has been conjugated to Fragment C.

12. The conjugated vaccine according to claim 11, wherein the antigen is a capsular polysaccharide from a bacterium.

13. The conjugated vaccine according to claim 12, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X; Streptococcus group A, B, and C; Pneumococcus types 1,2, 3,4, 6A, 6B, 9, 14, 18F, 19F and 23; Staphylococcus aureus types 5 and 8 and Haemophilus influenzae type b.

14. The conjugated vaccine according to claim 11, wherein the antigen is a capsular polysaccharide from a fungus.

15. The method according to claim 14, wherein the fungus is selected from the group consisting Candida albicans and Cryptococcus neoformans.